Brokerages expect HEXO Corp. (NASDAQ:HEXO) to report earnings of ($0.04) per share for the current fiscal quarter, according to Zacks. Eight analysts have issued estimates for HEXO’s earnings, with the lowest EPS estimate coming in at ($0.05) and the highest estimate coming in at ($0.01). The company is scheduled to report its next earnings report on Thursday, September 12th.

On average, analysts expect that HEXO will report full-year earnings of ($0.15) per share for the current financial year, with EPS estimates ranging from ($0.24) to ($0.04). For the next fiscal year, analysts expect that the company will report earnings of $0.03 per share, with EPS estimates ranging from ($0.25) to $0.30. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that follow HEXO.

HEXO (NASDAQ:HEXO) last released its earnings results on Thursday, June 13th. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. The company had revenue of $11.98 million during the quarter, compared to the consensus estimate of $10.96 million.

A number of research analysts recently issued reports on HEXO shares. Oppenheimer set a $14.00 price target on ADMA Biologics and gave the company a “buy” rating in a report on Tuesday, June 25th. Bank of America set a $10.00 price target on HEXO and gave the company a “buy” rating in a report on Thursday, June 13th. Desjardins restated a “buy” rating on shares of Horizons Enhcd Inc Eqy Cl E Unt Etf in a report on Thursday, April 25th. AltaCorp Capital restated an “outperform” rating on shares of HEXO in a report on Thursday, April 4th. Finally, Zacks Investment Research upgraded HAYS PLC/ADR from a “sell” rating to a “hold” rating in a report on Tuesday, June 18th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $8.63.

A number of large investors have recently made changes to their positions in the stock. Cim LLC purchased a new position in shares of HEXO during the 1st quarter worth approximately $208,000. EP Wealth Advisors LLC purchased a new position in shares of HEXO during the 1st quarter worth approximately $1,572,000. Oppenheimer & Co. Inc. purchased a new position in shares of HEXO during the 1st quarter worth approximately $104,000. CLARET ASSET MANAGEMENT Corp purchased a new position in shares of HEXO during the 1st quarter worth approximately $255,000. Finally, Strategic Financial Services Inc purchased a new position in shares of HEXO during the 1st quarter worth approximately $66,000.

NASDAQ:HEXO traded down $0.30 during mid-day trading on Friday, reaching $4.85. 5,814,845 shares of the company’s stock traded hands, compared to its average volume of 3,492,660. HEXO has a 12-month low of $3.02 and a 12-month high of $8.40. The firm’s 50 day moving average is $5.84.

HEXO Company Profile

HEXO Corp., through its subsidiary, HEXO Operations Inc, produces, markets, and sells cannabis in Canada. The company offers dried cannabis under the Time of Day and H2 lines; Elixir, a cannabis oil sublingual mist product line; and Decarb, an activated fine-milled cannabis powder product. It provides its products under the HEXO and Hydropothecary brand names.

Featured Story: What is the formula for the cash asset ratio?

Get a free copy of the Zacks research report on HEXO (HEXO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for HEXO (NASDAQ:HEXO)

Receive News & Ratings for HEXO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HEXO and related companies with MarketBeat.com's FREE daily email newsletter.